Mesoblast's Cell Therapy for Graft-Versus-Host Disease Wins FDA Approval; Stock Soars 42%
Mesoblast's Cell Therapy for Graft-Versus-Host Disease Wins FDA Approval; Stock Soars 42%The FDA has approved Mesoblast Limited's (NASDAQ: MESO) Ryoncil (remestemcel-L), marking it as the first mesenc...